In the world of psoriatic arthritis (PsA) treatments, a new head-to-head comparison has generated significant discussion. A recent study directly comparing Bimzelx and Skyrizi showed that for the primary goal of joint improvement, Bimzelx outperformed Skyrizi. This result is noteworthy as it marks the first time a treatment has demonstrated superiority over an IL-23 inhibitor like Skyrizi in PsA. For patients and clinicians, this data provides a clearer picture of the relative strengths of these two advanced biologic therapies.
Understanding psoriatic arthritis
Psoriatic arthritis is a chronic inflammatory condition that affects both the skin and joints. It is an autoimmune disease, meaning the body’s own immune system mistakenly attacks healthy tissue. This assault leads to joint pain, stiffness, and swelling, often accompanied by the characteristic skin plaques of psoriasis. Managing PsA involves controlling this inflammation to prevent irreversible joint damage and improve quality of life. All treatment decisions should be made in consultation with a qualified physician who can assess your specific condition.
The BE OPTIMAL trial: a head-to-head comparison
The recent study was a direct face-off between Bimzelx and Skyrizi, involving adults with active PsA who were either new to biologic treatments or had not responded adequately to a single TNF inhibitor. The main yardstick for success was the ACR50 response. This metric, established by the American College of Rheumatology, is a composite measure that signifies a substantial clinical improvement.
- To meet ACR50, a patient must show at least a 50% improvement in the number of tender and swollen joints.
- They must also show a 50% improvement in at least three of five other disease markers, including pain, inflammation, and physical function.
Achieving this level of response is considered a strong indicator of meaningful relief from the daily burden of psoriatic arthritis.
How Bimzelx outperformed Skyrizi on the primary goal
The results for the primary endpoint were clear. After 16 weeks of treatment, 49% of patients taking Bimzelx achieved an ACR50 response. This was significantly higher than the 38% of patients who reached the same milestone on Skyrizi. This finding is important because it demonstrates a statistically significant advantage for Bimzelx in overall joint disease activity reduction.
As Professor Iain McInnes of the University of Glasgow noted, achieving ACR50 responses correlates closely with clinically meaningful reductions in disease activity and inflammation. It is not just a number, but a reflection of improved quality of life for patients. The trial also showed that Bimzelx worked faster on this metric, with 20% of its users hitting ACR50 by week four, compared to just 7% for Skyrizi.
A closer look at skin clearance and other measures
While the joint improvement results were statistically significant, the story for secondary goals was more nuanced. Bimzelx showed what is called “numerical superiority” in several other areas, but these differences were not large enough to be statistically conclusive.
- Complete skin clearance: At week 16, 53% of Bimzelx patients achieved completely clear skin, compared to 47% of those on Skyrizi. While better, this was not a statistically significant win.
- Minimal Disease Activity (MDA): This holistic measure assesses overall disease control across multiple domains. Here, Bimzelx edged out Skyrizi with 43% of patients achieving MDA versus 40%.
This is a key detail for a careful reader. A numerical advantage is encouraging, but without statistical significance, it cannot be definitively claimed as superior. It suggests a trend, but more data would be needed to confirm it.
A tale of two interleukins: how the drugs work
Bimzelx and Skyrizi target inflammation in different ways. Think of the immune system’s inflammatory signals as a messy chain of command. Skyrizi works by blocking a protein called IL-23, which is like an officer that gives orders early in the process. By neutralizing IL-23, it prevents a cascade of downstream inflammatory signals from being sent.
Bimzelx, on the other hand, works further down the chain. It is the first and only approved treatment to selectively inhibit two specific inflammatory proteins at once: IL-17A and IL-17F. These are like two front-line soldiers carrying out the attack on healthy tissue. Bimzelx neutralizes both, providing a dual-action blockade. Your doctor can determine the most appropriate treatment for your specific medical situation and health profile.
The broader treatment landscape for psoriatic arthritis
Bimzelx and Skyrizi are part of a growing arsenal of advanced biologic drugs for PsA. They join other classes of medication, such as TNF inhibitors like Humira and single IL-17 inhibitors like Cosentyx. Choosing the right one depends on many factors, including the specific symptoms a patient experiences, their medical history, and how they have responded to previous treatments.
A critical part of managing a chronic condition like PsA is ensuring an uninterrupted supply of your prescribed biologic treatment. This is where the reliability of your pharmacy partner becomes paramount. Licensed international pharmacies like IsraelPharm play a key role by providing a consistent supply chain. They ensure patients receive the exact branded medication prescribed by their doctor, supporting treatment continuity without unexpected gaps.
| Treatment | How it works | Pros | Cons | Typical use |
|---|---|---|---|---|
| Bimzelx (bimekizumab) | Dual inhibitor of IL-17A and IL-17F | Strong efficacy for both joint and skin symptoms. Rapid onset of action shown in trials. | As a newer drug, long-term real-world data is still accumulating. | For active PsA, often after other treatments have been tried. |
| Skyrizi (risankizumab) | Inhibitor of IL-23 | Very effective, particularly for skin clearance. Less frequent dosing schedule. | Showed lower rates of joint improvement vs. Bimzelx in a head-to-head trial. | For active PsA and psoriasis, with a profile strong in skin manifestations. |
| Humira (adalimumab) | TNF-alpha inhibitor | Long track record of safety and efficacy in millions of patients. | Efficacy can wane over time for some patients. More frequent injections. | Often a first-line biologic for PsA and other autoimmune conditions. |
| Cosentyx (secukinumab) | Inhibitor of IL-17A | Proven effectiveness for joints and skin. Well-established in PsA treatment. | May have a slightly slower onset for skin clearance compared to newer agents. | A widely used first or second-line biologic for active PsA. |
How to access Bimzelx or Skyrizi through IsraelPharm
For patients prescribed a long-term therapy like Bimzelx or Skyrizi, ensuring a reliable and affordable supply is a primary concern. IsraelPharm provides a straightforward solution for accessing these advanced medications. The service is built around providing confidence and consistency for patients managing chronic conditions.
Patients sourcing their treatment through IsraelPharm benefit from key advantages. As a licensed international pharmacy, it operates under strict regulatory oversight and supplies the exact branded product prescribed by your physician, ensuring access and treatment continuity. This removes the uncertainty of local stock shortages and allows for a predictable treatment schedule with medication delivered directly to your home.
This level of reliability and access also comes with a significant financial benefit. The cost of Bimzelx or Skyrizi through IsraelPharm is substantially lower than US retail prices, making long-term treatment more sustainable. A valid prescription from a licensed physician is required to place an order. You can learn more about the process on the IsraelPharm website.
Price comparison table
| Brand | Form and strength | U.S. Retail | IsraelPharm price |
|---|---|---|---|
| Bimzelx (bimekizumab) | 2 autoinjector pens, 160mg/ ml | $17,430 | $3,000 |
| Skyrizi (risankizumab) | Prefilled injection pen, 150 mg/mL | $30,010 | $5,200 |
| Skyrizi (risankizumab) | Prefilled syringe, 150 mg/mL, 150 mg/mL | $31,700 | $5,200 |
Further reading
- Explore how to source Skyrizi from IsraelPharm: IsraelPharm blogs
- Psoriatic Arthritis information: Medline Plus
- First head-to-head study in active psoriatic arthritis: UCB press release
Frequently asked questions
If Bimzelx outperformed Skyrizi, does that mean it’s a better drug?
Not necessarily for every person. The trial showed that, on average, Bimzelx was statistically superior for the primary joint-related endpoint of ACR50. However, the “best” drug is always specific to the individual patient. Factors like the prominence of skin versus joint symptoms, other health conditions, and response to past treatments all play a role. This important decision must be made with your rheumatologist, who can weigh the evidence from trials like this one against your personal health profile to choose the right treatment for you.
What is the main difference in how Bimzelx and Skyrizi treat psoriatic arthritis?
The main difference lies in their targets within the immune system. Skyrizi blocks a single inflammatory signaling protein called IL-23. This protein acts earlier in the inflammatory cascade. In contrast, Bimzelx is the only approved therapy that blocks two different proteins, IL-17A and IL-17F, which are more directly involved in the inflammatory attack on tissues. This dual-action mechanism is what sets Bimzelx apart from Skyrizi and other biologics used to treat psoriatic arthritis.
How important is complete skin clearance in psoriatic arthritis treatment?
Complete skin clearance is a very important goal for many patients, as the skin plaques associated with psoriasis can be uncomfortable and affect confidence. In the head-to-head trial, both Bimzelx and Skyrizi performed very well on this measure, achieving high rates of skin clearance. While joint pain and damage are central to PsA, achieving clear or nearly clear skin significantly improves a patient’s overall quality of life. Many modern treatments, including Bimzelx, are highly effective at addressing both the joint and skin components of the disease.
What does ACR50 mean for a patient with psoriatic arthritis?
ACR50 is a specific, measurable milestone that translates to significant real-world improvement for a patient. It means their joint swelling and tenderness have been reduced by at least half. It also requires a 50% improvement in other key areas like pain and physical function. When comparing Bimzelx and Skyrizi, reaching ACR50 in a trial means Bimzelx is providing a substantial and clinically meaningful reduction in the signs and symptoms of psoriatic arthritis. It is a strong indicator that the therapy is effectively controlling the disease.
Can I get my exact prescription for Bimzelx or Skyrizi filled reliably?
Yes, ensuring a reliable supply of your prescribed medication is crucial for managing psoriatic arthritis. A licensed international pharmacy like IsraelPharm specializes in providing access and continuity for branded medications like Bimzelx and Skyrizi. They fill your prescription with the exact product specified by your doctor, not a substitute. This service provides peace of mind, ensuring your treatment plan can proceed without interruptions from local pharmacy stock issues. Medications are delivered directly to your home, simplifying the process of managing your long-term therapy.
Glossary
ACR50: A standard clinical trial measure representing a 50% or greater improvement in psoriatic arthritis symptoms as defined by the American College of Rheumatology.
Biologic: A type of medication derived from living organisms that targets specific parts of the immune system to treat diseases like psoriatic arthritis.
Interleukin (IL): A group of naturally occurring proteins that act as messengers between white blood cells, playing a key role in activating inflammation.
Minimal Disease Activity (MDA): A composite endpoint in rheumatology measuring a low level of disease activity across multiple domains including joints, skin, and patient-reported outcomes.
Psoriatic Arthritis (PsA): A chronic autoimmune condition characterized by inflammation in the joints and skin, combining symptoms of arthritis and psoriasis.
TNF inhibitor: A class of biologic drugs that block the action of Tumor Necrosis Factor, a protein that promotes inflammation in many autoimmune diseases.
